

Supporting Information

**Remote C(sp³)-H Activation: Palladium-Catalyzed Intermolecular
Arylation and Alkynylation with Organolithiums and Terminal
Alkynes**

Peng Chen,^a Zhi-Yong Wang,^a Jia-Xin Wang,^b Xiao-Shui Peng^{*a,b} and Henry N.C.
Wong^{*a,b}

^a*Department of Chemistry, and State Key Laboratory of Synthetic Chemistry, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong SAR, China.*

^b*School of Science and Engineering, The Chinese University of Hong Kong (Shenzhen), Shenzhen, China.*

Table of contents


1. General Information	3
2. Preparation of Substrates.....	4
3. Optimization of Reaction Conditions	7
4. Experimental Section	17
5. X-ray Crystallographic Data.....	39
6. References	40
7. Copies of ¹ H NMR, ¹³ C NMR, ¹⁹ F NMR Spectra	41

1. General Information

All reactions were carried out under an atmosphere of dry argon with the rigid exclusion of air and moisture using standard Schlenk techniques or in a glovebox unless otherwise specified. Reactions were magnetically stirred and monitored by thin layer chromatography (TLC) on MERCK silica gel 60 F254 coated on aluminum plates. Visualization was accomplished by irradiation with UV light at 254 nm followed by staining with ceric ammonium molybdate (CAM). Organic solvents were concentrated under reduced pressure at appropriate temperature on a rotary evaporator unless otherwise stated. Column chromatography was performed on silica gel (300–400 mesh). Preparative thin-layer chromatography (PTLC) was performed on glass plates (20 × 20 cm) impregnated with silica gel 60 F254 (0.3–0.4 mm thickness). Pentane, diethyl ether, THF and toluene for reactions were dried over sodium wire and distilled under an atmosphere of dry Ar. CH₂Cl₂ was dried over calcium hydride and distilled under an atmosphere of dry Ar. NMR spectra were recorded on a Bruker Ultrashield 400 Plus NMR spectrometer (400 MHz for ¹H, 101 MHz for ¹³C, 377 MHz for ¹⁹F) or Bruker Ascend 500 NMR spectrometer (500 MHz for ¹H, 126 MHz for ¹³C, 471 MHz for ¹⁹F). Chemical shifts of ¹H NMR and ¹³C NMR spectra were reported as parts per million in δ scale using residual solvent signal as internal standard (note: CDCl₃ referenced at δ 7.26 in ¹H and δ 77.0 for central line of the triplet in ¹³C;). Data are represented as follows: chemical shift, integration, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad) and coupling constant (*J*, Hz). High resolution mass spectra (HRMS) were obtained on a Bruker Solarix 9.4T ICR Mass Spectrometer or Thermo Q Exactive Focus Orbitrap Mass Spectrometer. Melting points were measured on a STUART Melting Point Apparatus SMP40 and were uncorrected. GC-MS analyses were performed on an Agilent 7890B system with an Agilent 5977B MSD. Unless otherwise noted, purchased chemicals were used without further purification. All terminal alkynes **8** were commercially available.


2. Preparation of Substrates

2.1 Synthesis of Aryl bromides and Aryl trifluoromethanesulfonates



Aryl bromide **1a** was commercially available, and compound **1b**, **1d**, **1e** and **1f** were known compounds in the literature.¹ Attempt on replacing *t*-Bu group with other groups was also performed, which however only lead to direct cross-coupling reactions with on observation of 1,4-palladium shift product, proving the great significance of steric hindrance for the production of C–H activation in this reaction.

2,6-di-*tert*-butyl-4-methylphenyl trifluoromethanesulfonate (**1c**)




Under an argon atmosphere, to an oven-dried Schlenk flask containing a magnetic stir bar, was added 2,6-di-*tert*-butyl-4-methylphenol (0.88 g, 4.0 mmol), and diethyl ether (20 mL). The reaction mixture was cooled to $-78\text{ }^\circ\text{C}$, and then a solution of *n*-BuLi (1.6 M in hexanes, 3.75 mL, 6.0 mmol) was added slowly via syringe. The mixture was allowed to warm to room temperature and stirred for 30 min. The mixture was cooled back to $-78\text{ }^\circ\text{C}$, and triflic anhydride (1.35 mL, 8.0 mmol) was added slowly via syringe. The mixture was allowed to warm to room temperature and stirred for 12 h. The reaction was quenched with a saturated aqueous solution of NaHCO_3 (30 mL). The organic layer was separated, washed with brine, dried over Na_2SO_4 ,

filtered and concentrated in vacuo. Chromatographic purification on silica gel (silica gel 20 g; eluent: 100% Hexane) to the product **1c** (422 mg, 30% yield) as a colorless oil. $R_f = 0.8$ (Hexane = 100%) $^1\text{H NMR}$ (400 MHz, CDCl_3) $\delta = 7.18$ (s, 2H), 2.35 (s, 3H), 1.46 (s, 18H) ppm. $^{13}\text{C NMR}$ (101 MHz, CDCl_3) $\delta = 144.8, 137.7, 136.3, 129.7, 127.4, 37.2, 32.6, 21.1$ ppm. $^{19}\text{F NMR}$ (471 MHz, CDCl_3) $\delta = -72.31$ ppm. HRMS m/z (ESI) calcd. for $\text{C}_{16}\text{H}_{23}\text{F}_3\text{O}_3\text{S}$ $[\text{M}+\text{Na}]^+$: 375.1208; found: 375.1212.

2.2 Synthesis of Terminal Alkynes 8

The terminal alkyne **8ab** was synthesized, and the other terminal alkynes are commercially available.




(R)-2,8-dimethyl-6-(prop-2-yn-1-yloxy)-2-((4R,8R)-4,8,12-trimethyltridecyl)chromane

(**8ab**)

To a mixture of (+) δ -Tocopherol (1.02 g, 2.5 mmol, 1.0 equiv) and anhydrous K_2CO_3 (1.41 g, 10.12 mmol, 4.0 equiv) in acetone (30 mL) was added propargyl bromide (0.30 mL, 3.75 mmol, 1.5 equiv) at 65 °C. After vigorous stirring for 12h, cooled to room temperature. And aqueous NH_4Cl was added to the reaction mixture. The organic layer was separated, and the aqueous layer was extracted with EtOAc. The combined organic layers were dried over anhydrous Na_2SO_4 , filtered, and concentrated under reduced pressure. The residue was purified through column chromatography (Hexane/ Et_2O = 20/1) over silica gel, to afford (R)-2,8-dimethyl-6-(prop-2-yn-1-yloxy)-2-((4R,8R)-4,8,12-trimethyltridecyl)chromane (**8ab**) (0.90 g, 52%) as yellow oil. R_f = 0.6 (Hexane/ Et_2O = 10/1) 1H NMR (500 MHz, $CDCl_3$) δ = 6.66 (d, J = 2.8 Hz, 1H), 6.56 (dd, J = 13.1, 5.6 Hz, 1H), 4.62 (d, J = 2.4 Hz, 2H), 2.78 – 2.68 (m, 2H), 2.55 – 2.47 (m, 1H), 2.17 (s, 3H), 1.86 – 1.72 (m, 2H), 1.64 – 1.50 (m, 4H), 1.50 – 1.35 (m, 4H), 1.34 – 1.24 (m, 10H), 1.19 – 1.02 (m, 6H), 0.91 – 0.84 (m, 12H) ppm. ^{13}C NMR (126 MHz, $CDCl_3$) δ = 150.0, 146.9, 127.3, 121.0, 115.8, 112.5, 79.3, 75.7, 75.0, 56.5, 40.0, 39.4, 37.4, 37.4, 37.3, 32.8, 32.7, 31.2, 28.0, 24.8, 24.4, 24.1, 22.7, 22.7, 22.6, 21.0, 19.7, 19.6, 16.2 ppm. HRMS m/z (APCI) calcd. for $C_{30}H_{48}O_2$ $[M+H]^+$: 441.3727; found: 441.3725.

3. Optimization of Reaction Conditions


3.1.1 Table S1: Effect of Addition Rate of Organolithium Reagents



^a Entry	1a	2a	^b t	^c Yield (%)
1	1.0 eq.	3.0 eq.	0.5 + 11.5	53%
2	1.0 eq.	3.0 eq.	1 + 11 h	65%
3	1.0 eq.	3.0 eq.	1.5 + 10.5 h	53%
4	1.0 eq.	3.0 eq.	2 + 10 h	50%
5	1.0 eq.	3.0 eq.	2.5 + 9.5 h	77%
6	1.0 eq.	3.0 eq.	3 + 9.5 h	63%
7	1.0 eq.	3.0 eq.	3.5 + 8.5 h	57%
8	1.0 eq.	3.0 eq.	4 + 8 h	54%
9	1.0 eq.	3.0 eq.	4.5 + 7.5 h	56%
10	1.0 eq.	3.0 eq.	5 + 7 h	47%

^aReaction conditions unless otherwise noted: **1a** (0.10 mmol), **2a** (0.30 mmol), Pd₂dba₃ (10 mol%), RuPhos (40 mol%), K₃PO₄ (3.0 eq.), toluene (2.0 mL) were used, 100 °C, under Ar for 12 h. ^bFor total 12 h reaction time, the first **red** number means the dropwise addition time of **2a**, and the second black number means further continuous reaction time. ^cYield was determined by ¹H NMR analysis with CH₂Br₂ as an internal standard.


3.1.2 Table S2: Effect of Amounts of Base



^a Entry	1a	2a	K_3PO_4	^b Yield (%)
1	1.0 eq.	3.0 eq.	1.0 eq.	57%
2	1.0 eq.	3.0 eq.	1.5 eq.	59%
3	1.0 eq.	3.0 eq.	2.0 eq.	63%
4	1.0 eq.	3.0 eq.	2.5 eq.	61%
5	1.0 eq.	3.0 eq.	3.0 eq.	77%
6	1.0 eq.	3.0 eq.	3.5 eq.	60%
7	1.0 eq.	3.0 eq.	4.0 eq.	55%

^aReaction conditions unless otherwise noted: **1a** (0.10 mmol), **2a** (0.30 mmol), Pd_2dba_3 (10 mol%), RuPhos (40 mol%), K_3PO_4 (x eq.), toluene (2.0 mL) were used, 100 °C, under Ar for 12 h. ^bYield was determined by ^1H NMR analysis with CH_2Br_2 as an internal standard.


3.2.1 Table S3: Effect of the Base



^a Entry	1a	8a	Base	^b Yield (%)
1	1.0 eq.	1.5 eq.	LiOMe	0
2	1.0 eq.	1.5 eq.	KO ^t Bu	0
3	1.0 eq.	1.5 eq.	NaO ^t Bu	0
4	1.0 eq.	1.5 eq.	Et ₃ N	0
5	1.0 eq.	1.5 eq.	K ₂ CO ₃	18
6	1.0 eq.	1.5 eq.	Cs ₂ CO ₃	32
7	1.0 eq.	1.5 eq.	CsPivO	0
8	1.0 eq.	1.5 eq.	CsF	26
9	1.0 eq.	1.5 eq.	NaHCO ₃	4
10	1.0 eq.	1.5 eq.	NaOAc	3
11	1.0 eq.	1.5 eq.	KOAc	0
12	1.0 eq.	1.5 eq.	LiOAc	2
13	1.0 eq.	1.5 eq.	KHMDS	0
14	1.0 eq.	1.5 eq.	KF	3
15	1.0 eq.	1.5 eq.	K₃PO₄	37
16	1.0 eq.	1.5 eq.	K ₃ PO ₄	31 ^c


^aReaction conditions unless otherwise noted: **1a** (0.10 mmol), **8a** (0.15 mmol), Pd₂(dba)₃, SPhos, base (0.30 mmol), toluene (2.0 mL) were used, 110 °C, under Ar for 24 h. ^bYield was determined by ¹H NMR analysis with CH₂Br₂ as an internal standard. ^c140 °C for 24 h.

3.2.2 Table S4: Effect of the Ligand




^a Entry	1a	8a	Ligand	^b Yield (%)
1	1.0 eq.	1.5 eq.	SPhos	37
2	1.0 eq.	1.5 eq.	CPhos	35
3	1.0 eq.	1.5 eq.	XPhos	49
4	1.0 eq.	1.5 eq.	<i>t</i> -ButylMePhos	26
5	1.0 eq.	1.5 eq.	DavePhos	43
6	1.0 eq.	1.5 eq.	<i>t</i> -BuxPhos	0
7	1.0 eq.	1.5 eq.	<i>t</i> -Bu-xantPhos	0
8	1.0 eq.	1.5 eq.	PhDavePhos	0
9	1.0 eq.	1.5 eq.	RuPhos	50
10	1.0 eq.	1.5 eq.	SIMes•HCl	0
11	1.0 eq.	1.5 eq.	IcHex•HCl	0
12	1.0 eq.	1.5 eq.	IPr•HCl	0
13	1.0 eq.	1.5 eq.	IAd•HBF ₄	0
14	1.0 eq.	1.5 eq.	CyJohnPhos	37
15	1.0 eq.	1.5 eq.	MePhos	32

^aReaction conditions unless otherwise noted: **1a** (0.10 mmol), **8a** (0.15 mmol), $\text{Pd}_2(\text{dba})_3$, ligand, K_3PO_4 (0.30 mmol), toluene (2.0 mL) were used, $110\text{ }^\circ\text{C}$, under Ar for 24 h. ^bYield was determined by ^1H NMR analysis with CH_2Br_2 as an internal standard.




3.2.3 Table S5: Effect of the Palladium Catalyst



^a Entry	1a	8a	[Pd]	^b Yield (%)
1	1.0 eq.	1.5 eq.	$Pd(PPh_3)_4$	22
2	1.0 eq.	1.5 eq.	$Pd(OAc)_2$	0
3	1.0 eq.	1.5 eq.	$Pd(TFA)_2$	22
4	1.0 eq.	1.5 eq.	$Pd(dppf)Cl_2 \cdot DCM$	33
5	1.0 eq.	1.5 eq.	$Pd(dba)_2$	37
6	1.0 eq.	1.5 eq.	$Pd(PPh_3)_2Cl_2$	17
7	1.0 eq.	1.5 eq.	$Pd(PhCN)_2Cl_2$	17
8	1.0 eq.	1.5 eq.	$Pd(Cy_3)_2Cl_2$	39
9	1.0 eq.	1.5 eq.	$Pd(dppf)_2Cl_2$	23
10	1.0 eq.	1.5 eq.	$Pd_2(dba)_3$	50

^aReaction conditions unless otherwise noted: **1a** (0.10 mmol), **8a** (0.15 mmol), [Pd], ligand, K_3PO_4 (0.30 mmol), toluene (2.0 mL) were used, 110 °C, under Ar for 24 h. ^bYield was determined by 1H NMR analysis with CH_2Br_2 as an internal standard.


3.2.4 Table S6: Effect of the Solvent



^a Entry	1a	8a	Solvent	^b Yield (%)
1	1.0 eq.	1.5 eq.	Toluene	50
2	1.0 eq.	1.5 eq.	<i>o</i> -DCB	0
3	1.0 eq.	1.5 eq.	Benzene	7
4	1.0 eq.	1.5 eq.	DME	10
5	1.0 eq.	1.5 eq.	DMF	0
6	1.0 eq.	1.5 eq.	1,4-dioxane	60
7	1.0 eq.	1.5 eq.	MeCN	23
8	1.0 eq.	1.5 eq.	DMSO	0
9	1.0 eq.	1.5 eq.	<i>m</i> -Xylene	10

^aReaction conditions unless otherwise noted: **1a** (0.10 mmol), **8a** (0.15 mmol), [Pd], ligand, K_3PO_4 (0.30 mmol), solvent (2.0 mL) were used, $110\text{ }^\circ\text{C}$, under Ar for 24 h. ^bYield was determined by ^1H NMR analysis with CH_2Br_2 as an internal standard.


3.2.5. Table S7: Effect of the ratio of Pd₂dba₃/RuPhos



^a Entry	1a	8a	Pd ₂ (dba) ₃	RuPhos	^b Yield (%)
1	1.0 eq.	1.5 eq.	5 %	5 %	0
2	1.0 eq.	1.5 eq.	5 %	10 %	16
3	1.0 eq.	1.5 eq.	5 %	15 %	25
4	1.0 eq.	1.5 eq.	5 %	20 %	53
5	1.0 eq.	1.5 eq.	5 %	25 %	32
6	1.0 eq.	1.5 eq.	5 %	30 %	19
7	1.0 eq.	1.5 eq.	5 %	40	11

^aReaction conditions unless otherwise noted: **1a** (0.10 mmol), **8a** (0.15 mmol), Pd₂dba₃, RuPhos, K₃PO₄ (0.30 mmol), toluene (2.0 mL) were used, 110 °C, under Ar for 24 h. ^bYield was determined by ¹H NMR analysis with CH₂Br₂ as an internal standard.


3.2.6 Table S8: Effect of the amount of Toluene



^a Entry	1a	8a	Toluene (mL)	^b Yield (%)
1	1.0 eq.	1.5 eq.	1.0	22
2	1.0 eq.	1.5 eq.	1.5	25
3	1.0 eq.	1.5 eq.	2.0	35
4	1.0 eq.	1.5 eq.	2.5	35
5	1.0 eq.	1.5 eq.	3.0	35

^aReaction conditions unless otherwise noted: **1a** (0.10 mmol), **8a** (0.15 mmol), Pd₂dba₃, RuPhos, K₃PO₄ (0.30 mmol), toluene, 110 °C, under Ar for 24 h. ^bYield was determined by ¹H NMR analysis with CH₂Br₂ as an internal standard.

3.2.7 Table S9: Effect of the amount of K₃PO₄




^a Entry	1a	8a	K ₃ PO ₄ (equiv.)	^b Yield (%)
1	1.0 eq.	1.5 eq.	1.0	6
2	1.0 eq.	1.5 eq.	1.5	10
3	1.0 eq.	1.5 eq.	2.0	26
4	1.0 eq.	1.5 eq.	2.5	28
5	1.0 eq.	1.5 eq.	3.0	48
6	1.0 eq.	1.5 eq.	3.5	26
7	1.0 eq.	1.5 eq.	4.0	24
8	1.0 eq.	1.5 eq.	4.5	20

^aReaction conditions unless otherwise noted: **1a** (0.10 mmol), **8a** (0.15 mmol), Pd₂dba₃, RuPhos, K₃PO₄, toluene (2.0 mL), 110 °C, under

Ar for 24 h. ^bYield was determined by ¹H NMR analysis with CH₂Br₂ as an internal standard.

3.2.8 Table S10: Effect of the reaction time




^a Entry	t (h)	^b Yield (%)	^a Entry	t (h)	^b Yield (%)
1	2	9	9	20	28
2	4	27	10	24	31
3	6	34	11	30	31
4	8	22	12	42	32
5	12	29	13	48	45
6	14	32	14	12	56 ^c
7	16	43	15	24	75 ^c
8	18	19	16	24	68 ^d

^aReaction conditions: **1a** (0.10 mmol), **8a** (0.15 mmol), Pd₂dba₃ (5 mol%), RuPhos (20 mol %), K₃PO₄ (0.30 mmol), Toluene 1.0 mL were used, 110 °C, under Ar. ^bYield was determined by ¹H NMR analysis with CH₂Br₂ as an internal standard. ^cCompound **8a** was dissolved in 1.0 mL Toluene and added dropwise for 2 h. ^dadded dropwise for 1 h.

3.2.9 Table S11: Optimization of the Alkynylation with C(sp³)–H

Activation Reaction Conditions




^a entry	Pd ₂ dba ₃	RuPhos	t (h)	T (°C)	^b yield (%) ^b
1	5 %	20 %	24	110	54
2	5 %	20 %	24	110	96 (94)^c
3	5 %	20 %	18	110	92 (89) ^c
4	5 %	20 %	12	110	87 ^c
5	5 %	20 %	24	110	80 ^d
6	2.5 %	10 %	24	110	80 ^c
7	1 %	4 %	24	110	68 ^c

^aReaction conditions unless otherwise noted: **1a** (0.10 mmol), **8a** (0.15 mmol), Pd₂dba₃, RuPhos, K₃PO₄ (0.30 mmol), 1,4-dioxane (1.0 mL) were used, 110 °C, under Ar. ^bYield was determined by ¹H NMR analysis with CH₂Br₂ as an internal standard. Yield of isolated **9a** in parentheses. ^cCompound **8a** was dissolved in 1.0 mL 1,4-dioxane and added dropwise over 2 h. ^dAdded dropwise for 3 h.

4. Experimental Section


4.1 General Procedure for the Synthesis of 3, 5 and 7



After three times' evacuation and backfilling with dry argon, an oven-dried test tube equipped with magnetic stir bar was charged with Pd₂dba₃ (0.01 mmol), Ruphos (0.04 mmol), K₃PO₄ (0.30 mmol), and aryl bromides/triflates (**1**) (0.10 mmol), were added 2.0 mL toluene via argon-flushed syringes at 100 °C, and the freshly prepared organolithiums (**2**, **4** or **6**, 0.3 mmol) in THF was added dropwise via a syringe pump over 2.5 h. After 12 h, the test tube was allowed to be cooled down to room temperature, the reaction mixture was quenched by MeOH and passed through a short silica pad using EtOAc as an eluent. After concentrated under reduced pressure, the crude product was purified by column chromatography to afford desired products **3**, **5** or **7**, respectively.


For the preparation of organolithiums (0.45M in THF), procedures are as follows: After three times' evacuation and backfilling with dry argon, an oven-dried Schlenk flask equipped with magnetic stir bar was charged with corresponding aryl bromides (2.0 mmol), were added 2.0 mL THF via argon-flushed syringes, and the resulting solution was cooled to -78 °C in an acetone-dry ice bath. Then 2.5 mL *t*-BuLi (2.0 equiv, 1.6M in pentane) was added dropwise via an argon-flushed syringe, and the mixture was stirred at -78 °C for 30 min, after which the Schlenk flask was placed at room temperature and kept stirring for 30 min.

4.2 Optimized Procedure for Terminal Alkynes




Pd_2dba_3 (5 mol%), Ruphos (20 mol%), K_3PO_4 (0.30 mmol), and **1** (0.10 mmol, 1.0 equiv.) were carried out in test tube in glove box and then 1,4-dioxane (1.0 mL) was added to the test tube at room temperature. Alkynes **8** (0.15 mmol, 1.5 equiv.) dissolve in 1.0 mL 1,4-dioxane and was added dropwise via syringe pump over 2 h at 110 °C. After addition, the reaction system was stirred at 110 °C for another 22 h. It was then filtered through a pad of Celite using EtOAc and CH_2Cl_2 . The solvent was removed by reduced pressure and the residue was purified by column chromatograph or preparative thin-layer chromatography to afford the product **9**. Using the compound **1a** as the example: Pd_2dba_3 (0.005 mmol, 4.6 mg), K_3PO_4 (0.30 mmol, 64 mg) and Ruphos (0.02 mmol, 9.4 mg) were carried out in test tube in glove box and then the solution of compound **1a** (0.10 mmol, 33 mg) in 1.0 mL of 1,4-dioxane was added to the test tube at room temperature. Phenylacetylene **8a** (0.15 mmol, 20 μl) dissolve in 1.0 mL 1,4-Dioxane and was added dropwise by syringe pump over 2 h at 110 °C. After addition, the reaction system was stirred at 110 °C for another 22 h. It was then filtered through a pad of Celite using CH_2Cl_2 . The solvent was removed by reduced pressure and the residue was purified by column chromatograph (silica gel 8 g; eluent: 100% Hexane) to afford the product **9a** (32.6 mg, 94%).

Gram Scale Reaction




Pd_2dba_3 (0.15 mmol, 140 mg), K_3PO_4 (9.15 mmol, 2.07 g) and Ruphos (0.62 mmol, 295 mg) were carried out in round-bottom flask (200 mL) in glove box and then the solution of compound **1a** (3.05 mmol, 1.0 g) in 30.0 mL of 1,4-dioxane was added to the round-bottom flask at room temperature. Phenylacetylene **8a** (4.62 mmol, 0.51 mL) dissolve in 30 mL 1,4-dioxane and was added dropwise by syringe pump over 2 h at 110 °C. After addition, the reaction system was stirred at 110 °C for another 22 h. It was then filtered through a pad of Celite using CH_2Cl_2 . The solvent was removed by reduced pressure and the residue was purified by column chromatograph (silica gel 38 g; eluent: 100% Hexane) to afford the product **9a** (695 mg, 65%). $R_f = 0.8$ (Hexane = 100%).

Synthesis of (ethynyl-d)benzene **8a-D₁**⁴




To a solution of phenylacetylene (5.0 mmol, 0.55 mL) in dry THF (25 mL) was added *n*-BuLi (3.43 mL, 5.55 mmol, 1.60 M in hexane solution, 1.1 equiv.) dropwise at $-78\text{ }^{\circ}\text{C}$ under Ar atmosphere. After being stirred at the same temperature for 30 min, D₂O (2 mL) was added at the room temperature under Ar atmosphere, stirred continuously at the same temperature for 6 h. Then, the organic layer was separated and the aqueous layer was extracted with Et₂O. The combined organic layers were washed with Et₂O (20 mL \times 3), dried over anhydrous sodium sulfate and filtered. The solvent was removed under vacuum and the relative integrated intensities of the phenyl protons to the methylidyne protons, which had been 5.0 to 1.0 in the starting phenylacetylene, were now 5.0 to 0, indicating 93% deuteration at the C–H group and thus a 100% yield of (ethynyl-d)benzene (**8a-D₁**).

H/D-exchanged experiment




Pd₂dba₃ (0.005 mmol, 4.6 mg), K₃PO₄ (0.30 mmol, 64 mg) and RuPhos (0.02 mmol, 9.4 mg) were carried out in test tube in glove box and then the solution of compound **1a** (0.1 mmol, 33 mg) in 1.0 mL of 1,4-dioxane was added to the test tube at room temperature. Phenylacetylene **8a-D₁** (0.15 mmol) in 1.0 mL 1,4-dioxane and was added dropwise via syringe pump over 2 h at 110 °C. After addition, the reaction system was stirred at 110 °C for another 22 h. It was then filtered through a pad of Celite using CH₂Cl₂. The solvent was removed by reduced pressure


and the residue was purified by column chromatograph (silica gel 8 g; eluent: 100% Hexane) to afford the product **9a** (29.1 mg, 84%). $R_f = 0.8$ (Hexane = 100%).



1,3-di-tert-butyl-5-(2-methyl-1-phenylpropan-2-yl)benzene (3a): Column chromatography (SiO₂ 5 g, eluent: Hexane 100%) afforded **3a** (24.2 mg, 75%) as colorless oil. $R_f = 0.8$ (Hexane = 100%). ¹H NMR (500 MHz, CDCl₃) $\delta = 7.30$ (s, 1H), 7.19-7.11 (m, 5H), 6.80 (m, 2H), 2.87 (s, 2H), 1.38 (s, 6H), 1.34 (s, 18H) ppm. ¹³C NMR (126 MHz, CDCl₃) $\delta = 149.8, 147.6, 139.0, 130.4, 127.3, 125.7, 120.4, 119.4, 51.6, 39.1, 34.9, 31.5, 28.1$ ppm. Data were in accordance with those reported in the literature.¹




1,3-di-tert-butyl-5-(1-(2-methoxyphenyl)-2-methylpropan-2-yl)benzene (3b): Column chromatography (SiO₂ 5 g, eluent: Hexane and ethyl acetate (10:1, v/v)) afforded **3b** (32.8 mg, 93%) as colorless oil. $R_f = 0.6$ (Hexane/EA = 100/1). ¹H NMR (500 MHz, CDCl₃) $\delta = 7.24$ (s, 1H), 7.16-7.08 (m, 3H), 6.81-6.61 (m, 3H), 3.63 (s, 3H), 2.89 (s, 2H), 1.33 (s, 6H), 1.30 (s, 18H) ppm. ¹³C NMR (126 MHz, CDCl₃) $\delta = 158.0, 149.5, 148.4, 132.1, 127.7, 127.0, 120.4, 119.5, 119.3, 110.1, 54.9, 43.7, 39.5, 34.9, 31.6, 28.0$ ppm. Data were in accordance with those reported in the literature.²




1,3-di-tert-butyl-5-(1-(3-methoxyphenyl)-2-methylpropan-2-yl) (3c) Column chromatography (SiO₂ 5 g, eluent: Hexane and ethyl acetate (10:1, v/v)) afforded **3c** (24.3 mg, 69%) as colorless oil. $R_f = 0.6$ (Hexane/EA = 100/1). ¹H NMR (400 MHz, CDCl₃) $\delta = 7.27$ (s,


$J = 2.5$ Hz, 1H), 7.10 (d, $J = 1.7$ Hz, 2H), 7.05 (t, $J = 7.9$ Hz, 1H), 6.67 (dd, $J = 7.9, 2.2$ Hz, 1H), 6.46 (d, $J = 7.5$ Hz, 1H), 6.07 (s, 1H), 3.54 (s, 3H), 2.81 (s, 2H), 1.36 (s, 6H), 1.30 (s, 18H) ppm. ^{13}C NMR (101 MHz, CDCl_3) $\delta = 158.6, 149.8, 147.5, 140.5, 128.1, 122.9, 120.6, 119.4, 115.1, 111.9, 54.7, 51.7, 39.1, 34.9, 31.5, 28.2$ ppm. HRMS m/z (HESI-II) calcd. for $\text{C}_{25}\text{H}_{36}\text{O}$ $[\text{M}+\text{Na}]^+$: 375.2659; found: 375.2658.




1,3-di-tert-butyl-5-(1-(4-methoxyphenyl)-2-methylpropan-2-yl)benzene (3d): Column chromatography (SiO_2 5 g, eluent: Hexane and ethyl acetate (10:1, v/v)) afforded **3d** (22.6 mg, 64%) as colorless oil. $R_f = 0.6$ (Hexane/EA = 100/1). ^1H NMR (500 MHz, CDCl_3) $\delta = 7.25$ (s, 1H), 7.10 (s, 2H), 6.67 (s, 4H), 3.75 (s, 3H), 2.76 (s, 2H), 1.32 (s, 6H), 1.30 (s, 18H) ppm. ^{13}C NMR (126 MHz, CDCl_3) $\delta = 157.7, 149.7, 147.7, 131.3, 131.2, 120.5, 119.3, 112.8, 55.2, 50.6, 39.1, 34.9, 31.6, 28.0$ ppm. Data were in accordance with those reported in the literature.²




1,3-di-tert-butyl-5-(2-methyl-1-(*m*-tolyl)propan-2-yl)benzene (3e): Column chromatography (SiO_2 5 g, eluent: Hexane 100%) afforded **3e** (21.2 mg, 63%) as colorless oil. $R_f = 0.8$ (Hexane 100%). ^1H NMR (400 MHz, CDCl_3) $\delta = 7.25$ (s, 1H), 7.12 (d, $J = 1.7$ Hz, 2H), 7.03 (t, $J = 7.5$ Hz, 1H), 6.93 (d, $J = 7.5$ Hz, 1H), 6.62 (d, $J = 7.5$ Hz, 1H), 6.51 (s, 1H), 2.79 (s, 2H), 2.19 (s, 3H), 1.34 (s, 6H), 1.30 (s, 18H) ppm. ^{13}C NMR (101 MHz, CDCl_3) $\delta = 149.3, 147.4, 138.5, 136.2, 130.9, 127.0, 126.8, 126.0, 120.0, 119.0, 51.0, 38.6, 34.5, 31.1, 27.7, 20.9$ ppm. HRMS m/z (APCI II with DIP) calcd. for $\text{C}_{25}\text{H}_{36}$ $[\text{M}+\text{H}]^+$: 337.2890; found: 337.2889.



1,3-di-tert-butyl-5-(2-methyl-1-(*o*-tolyl)propan-2-yl)benzene (3f): Column chromatography (SiO₂ 5 g, eluent: Hexane 100%) afforded **3f** (25.2 mg, 75%) as colorless oil. *R_f* = 0.8 (Hexane 100%). ¹H NMR (500 MHz, CDCl₃) δ = 7.25 (s, 1H), 7.08-6.97 (m, 5H), 6.84 (d, *J* = 7.4 Hz, 1H), 2.83 (s, 2H), 1.74 (s, 3H), 1.43 (s, 6H), 1.27 (s, 18H) ppm. ¹³C NMR (126 MHz, CDCl₃) δ = 149.7, 147.2, 137.7, 137.3, 131.4, 130.1, 125.8, 124.8, 120.5, 119.5, 47.5, 39.7, 34.9, 31.4, 28.5, 19.4 ppm. HRMS *m/z* (APCI II with DIP) calcd. for C₂₅H₃₆ [M+H]⁺: 337.2890; found: 337.2889.




1,3-di-tert-butyl-5-(2-methyl-1-(3-(trifluoromethyl)phenyl)propan-2-yl)benzene (3g): Column chromatography (SiO₂ 5 g, eluent: Hexane 100%) afforded **3g** (32.4 mg, 83%) as colorless oil. *R_f* = 0.7 (Hexane 100%). ¹H NMR (500 MHz, CDCl₃) δ = 7.35 (d, *J* = 7.7 Hz, 1H), 7.27 (s, 1H), 7.21 (t, *J* = 7.7 Hz, 1H), 7.06 (s, 2H), 6.93 (d, *J* = 7.6 Hz, 1H), 6.82 (s, 1H), 2.89 (s, 2H), 1.37 (s, 6H), 1.28 (s, 18H) ppm. ¹³C NMR (126 MHz, CDCl₃) δ = 150.1, 146.3, 139.8, 133.5, 129.58 (q, *J* = 2.0 Hz), 127.6, 126.7 (q, *J* = 5.0 Hz), 124.2 (q, *J* = 272.2 Hz), 122.52 (q, *J* = 5.0 Hz), 120.4, 119.8, 51.4, 39.2, 34.9, 31.5, 28.2 ppm. ¹⁹F NMR (471 MHz, CDCl₃) δ = -62.53 (s) ppm. HRMS *m/z* (APCI II with DIP) calcd. for C₂₅H₃₃F₃ [M+H]⁺: 391.2607; found: 391.2601.




1,3-di-tert-butyl-5-(2-methyl-1-(2-(trifluoromethyl)phenyl)propan-2-yl)benzene (3h): Column chromatography (SiO₂ 5 g, eluent: Hexane 100%) afforded **3h** (36.7 mg, 94%) as

colorless oil. $R_f = 0.7$ (Hexane 100%). $^1\text{H NMR}$ (500 MHz, CDCl_3) $\delta = 7.60$ (d, $J = 7.8$ Hz, 1H), 7.32 (s, 1H), 7.22 (t, $J = 7.6$ Hz, 1H), 7.19 (d, $J = 1.7$ Hz, 2H), 7.14 (t, $J = 7.5$ Hz, 1H), 6.44 (d, $J = 7.8$ Hz, 1H), 3.14 (s, 2H), 1.38 (s, 6H), 1.34 (s, 18H) ppm. $^{13}\text{C NMR}$ (126 MHz, CDCl_3) $\delta = 150.1, 147.9, 138.1, 131.8, 130.5, 129.43$ (q, $J = 29.0$ Hz) 125.73 (q, $J = 4$ Hz), 124.69 (q, $J = 290.0$ Hz), 120.7, 119.6, 45.8, 45.7, 39.5, 35.0, 31.5, 28.7 ppm. $^{19}\text{F NMR}$ (471 MHz, CDCl_3) $\delta = -57.11$ (s) ppm. **HRMS** m/z (APCI II with DIP) calcd. for $\text{C}_{25}\text{H}_{33}\text{F}_3$ $[\text{M}+\text{H}]^+$: 391.2607; found: 391.2613.




1-(1-(2-(benzyloxy)phenyl)-2-methylpropan-2-yl)-3,5-di-tert-butylbenzene (3i): Column chromatography (SiO_2 5 g, eluent: Hexane 100%) afforded **3i** (16.3 mg, 38%) as colorless oil. $R_f = 0.8$ (Hexane/EA = 20/1). $^1\text{H NMR}$ (400 MHz, CDCl_3) $\delta = 7.39$ (ddd, $J = 27.2, 19.4, 7.3$ Hz, 6H), 7.18 (d, $J = 1.4$ Hz, 2H), 7.14 (t, $J = 8.4$ Hz, 1H), 6.90 (d, $J = 8.2$ Hz, 1H), 6.77 (t, $J = 7.4$ Hz, 1H), 6.70 (d, $J = 8.5$ Hz, 1H), 5.00 (s, 2H), 2.96 (s, 2H), 1.33 (s, 6H), 1.30 (s, 18H) ppm. $^{13}\text{C NMR}$ (101 MHz, CDCl_3) $\delta = 157.4, 149.7, 148.9, 137.7, 132.4, 128.5, 128.1, 127.7, 127.1, 127.1, 120.4, 120.0, 119.4, 111.5, 70.0, 43.8, 39.7, 35.0, 31.6, 27.8$ ppm. **HRMS** m/z (HESI-II) calcd. for $\text{C}_{31}\text{H}_{40}\text{O}$ $[\text{M}+\text{Na}]^+$: 451.2972; found: 451.2971.




1,3-di-tert-butyl-5-(1-(2-(2-methoxyethoxy)phenyl)-2-methylpropan-2-yl)benzene (3j): Column chromatography (SiO_2 5 g, eluent: Hexane 100%) afforded **3j** (25.4 mg, 64%) as colorless oil. $R_f = 0.8$ (Hexane/EA = 50/1). $^1\text{H NMR}$ (400 MHz, CDCl_3) $\delta = 7.25$ (s, 1H), 7.17-7.04 (m, 4H), 6.82-6.74 (m, 1H), 6.67 (d, $J = 7.4$ Hz, 1H), 5.02 (s, 2H), 3.68 (q, $J = 7.1$ Hz, 2H), 2.91 (s, 2H), 1.35 (s, 6H), 1.31 (s, 18H), 1.23 (t, $J = 7.1$ Hz, 3H) ppm. $^{13}\text{C NMR}$ (101 MHz, CDCl_3) $\delta = 156.3, 149.6, 148.4, 132.1, 128.2, 127.1, 120.6, 120.4, 119.4, 113.8, 93.4,$


64.0, 43.7, 39.5, 34.9, 31.6, 28.1, 15.1 ppm. **HRMS** m/z (HESI-II) calcd. for $C_{27}H_{40}O_2$ $[M+Na]^+$: 419.2920; found: 419.2921.




(4-(2-(3,5-di-tert-butylphenyl)-2-methylpropyl)phenyl)trimethylsilane (3k): Column chromatography (SiO_2 5 g, eluent: Hexane 100%) afforded **3k** (27.6 mg, 70%) as colorless oil. $R_f = 0.8$ (Hexane 100%). 1H NMR (400 MHz, CD_2Cl_2) $\delta = 7.31-7.22$ (m, 3H), 7.06 (s, 2H), 6.75 (d, $J = 7.8$ Hz, 2H), 2.80 (s, 2H), 1.33 (s, 6H), 1.27 (s, 18H), 0.21 (s, 9H) ppm. ^{13}C NMR (101 MHz, CD_2Cl_2) $\delta = 150.4, 148.1, 140.3, 137.6, 132.9, 130.4, 121.0, 119.9, 51.8, 39.7, 35.4, 31.8, 28.6, -0.9$ ppm. **HRMS** m/z (APCI II with DIP) calcd. for $C_{27}H_{42}Si$ $[M+H]^+$: 395.3129; found: 395.3132.




2-(2-(3,5-di-tert-butylphenyl)-2-methylpropyl)-1,3-dimethoxybenzene (3m): Column chromatography (SiO_2 5 g, eluent: Hexane 100%) afforded **3m** (37.5 mg, 98%) as colorless oil. $R_f = 0.8$ (Hexane/EA = 20/1). 1H NMR (500 MHz, $CDCl_3$) $\delta = 7.24$ (s, 1H), 7.20 (s, 2H), 7.12 (t, $J = 8.3$ Hz, 1H), 6.48 (d, $J = 8.3$ Hz, 2H), 3.60 (s, 6H), 2.97 (s, 2H), 1.33 (s, 6H), 1.32 (s, 18H) ppm. ^{13}C NMR (126 MHz, $CDCl_3$) $\delta = 159.0, 149.6, 149.1, 126.8, 120.2, 119.1, 116.4, 103.3, 55.1, 40.1, 36.7, 34.9, 31.6, 28.5$ ppm. **HRMS** m/z (HESI-II) calcd. for $C_{26}H_{38}O_2$ $[M+Na]^+$: 405.2766; found: 405.2764.




2-(2-(3,5-di-*tert*-butylphenyl)-2-methylpropyl)-1,3-dimethylbenzene (3n): Column chromatography (SiO₂ 5 g, eluent: Hexane 100%) afforded **3n** (27.0 mg, 77%) as colorless oil. $R_f = 0.8$ (Hexane 100%). ¹H NMR (500 MHz, CDCl₃) $\delta = 7.25$ (s, 1H), 6.99-6.94 (m, 3H), 6.89 (d, $J = 7.4$ Hz, 2H), 2.92 (s, 2H), 1.85 (s, 6H), 1.47 (s, 6H), 1.25 (s, 18H) ppm. ¹³C NMR (126 MHz, CDCl₃) $\delta = 149.7, 147.5, 138.4, 136.3, 128.1, 125.4, 120.7, 119.6, 43.3, 40.9, 34.8, 31.4, 29.4, 20.7$ ppm. HRMS m/z (APCI II with DIP) calcd. for C₂₆H₃₈ [M+H]⁺: 351.3046; found: 351.3041.



5-(2-(3,5-di-*tert*-butylphenyl)-2-methylpropyl)-2-methoxy-1,3-dimethylbenzene (3o): Column chromatography (SiO₂ 5 g, eluent: Hexane 100%) afforded **3o** (26.6 mg, 70%) as colorless oil. $R_f = 0.7$ (Hexane/EA = 50/1). ¹H NMR (400 MHz, CDCl₃) $\delta = 7.27$ (s, 1H), 7.12 (d, $J = 1.7$ Hz, 2H), 6.36 (s, 2H), 3.66 (s, 3H), 2.72 (s, 2H), 2.14 (s, 6H), 1.36 (s, 6H), 1.32 (s, 18H) ppm. ¹³C NMR (101 MHz, CDCl₃) $\delta = 155.0, 149.7, 147.7, 134.3, 130.8, 129.1, 120.5, 119.3, 59.6, 50.9, 39.0, 34.9, 31.5, 28.1, 16.0$ ppm. HRMS m/z (HESI-II) calcd. for C₂₇H₄₀O [M+Na]⁺: 403.2972; found: 403.2971.




1-(2-(3,5-di-*tert*-butylphenyl)-2-methylpropyl)-2,4-dimethoxybenzene (3p): Column chromatography (SiO₂ 5 g, eluent: Hexane 100%) afforded **3p** (33.3 mg, 87%) as colorless oil. $R_f = 0.7$ (Hexane/EA = 30/1). ¹H NMR (400 MHz, CDCl₃) $\delta = 7.25$ (s, 1H), 7.14 (d, $J = 1.5$ Hz, 2H), 6.55 (d, $J = 8.3$ Hz, 1H), 6.38 (d, $J = 2.3$ Hz, 1H), 6.29 (dd, $J = 8.3, 2.4$ Hz, 1H), 3.77 (s, 3H), 3.63 (s, 3H), 2.82 (s, 2H), 1.32 (s, 24H) ppm. ¹³C NMR (101 MHz, CDCl₃) $\delta = 159.0, 158.9, 149.4, 148.6, 132.2, 120.4, 120.2, 119.2, 103.3, 98.0, 55.3, 55.0, 43.1, 39.5, 34.9, 31.6, 27.9$ ppm. HRMS m/z (HESI-II) calcd. for C₂₆H₃₈O₂ [M+Na]⁺: 405.2763; found: 405.2764.




1-(1-(3,5-bis(trifluoromethyl)phenyl)-2-methylpropan-2-yl)-3,5-di-tert-butylbenzene (3q):

Column chromatography (SiO₂ 5 g, eluent: Hexane 100%) afforded **3q** (31.2 mg, 68%) as colorless oil. $R_f = 0.8$ (Hexane 100%). ¹H NMR (400 MHz, CDCl₃) $\delta = 7.58$ (s, 1H), 7.28 (s, 1H), 7.04–7.01 (m, 4H), 2.96 (s, 2H), 1.40 (s, 6H), 1.27 (s, 18H) ppm. ¹³C NMR (101 MHz, CDCl₃) $\delta = 150.4, 145.3, 141.3, 130.5, 130.2, 139.9, 122.0$ (q, $J = 341.5$ Hz), 119.65 (q, $J = 2.5$ Hz), 51.2, 39.3, 34.9, 31.6, 31.4, 28.1 ppm. ¹⁹F NMR (471 MHz, CDCl₃) $\delta = -62.82$ (s) ppm. HRMS m/z (APCI II with DIP) calcd. for C₂₆H₃₂F₆ [M+H]⁺: 459.2481; found: 459.2470.




2-(2-(3,5-di-tert-butylphenyl)-2-methylpropyl)-1,3,5-triisopropylbenzene (3r): Column chromatography (SiO₂ 5 g, eluent: Hexane 100%) afforded **3r** (42.6 mg, 95%) as colorless oil. $R_f = 0.8$ (Hexane 100%). ¹H NMR (400 MHz, CDCl₃) $\delta = 7.18$ (s, 1H), 6.95 (s, 2H), 6.88 (s, 2H), 3.01 (s, 2H), 2.96–2.78 (m, 3H), 1.46 (s, 6H), 1.22 (d, $J = 5.2$ Hz, 24H), 0.97 (d, $J = 6.7$ Hz, 12H) ppm. ¹³C NMR (101 MHz, CDCl₃) $\delta = 148.7, 147.6, 147.1, 145.6, 130.2, 120.6, 120.6, 120.0, 119.1, 39.8, 39.6, 34.4, 33.7, 31.1, 30.0, 29.4, 23.7$ ppm. HRMS m/z (APCI II with DIP) calcd. for C₃₃H₅₂ [M+H]⁺: 449.4142; found: 449.4060.




(3-(tert-butyl)-5-(2-methyl-1-phenylpropan-2-yl)phenyl)trimethylsilane (3s): Column chromatography (SiO₂ 5 g, eluent: Hexane 100%) afforded **3s** (27.1 mg, 80%) as colorless oil. $R_f = 0.8$ (Hexane 100%). ¹H NMR (400 MHz, CDCl₃) $\delta = 7.38$ (s, 1H), 7.33 (d, $J = 14.0$ Hz, 1H), 7.27 (s, 1H), 7.16–7.11 (m, 3H), 6.79 (dt, $J = 7.0, 3.4$ Hz, 2H), 2.84 (s, 2H), 1.34 (s, 6H),


1.30 (s, 9H), 0.25 (s, 9H) ppm. ^{13}C NMR (101 MHz, CDCl_3) δ = 149.4, 147.4, 139.0, 130.5, 128.1, 127.4, 127.2, 125.8, 124.1, 51.4, 38.9, 34.8, 31.5, 31.5, 28.1, 0.9 ppm. HRMS m/z (APCI II with DIP) calcd. for $\text{C}_{23}\text{H}_{34}\text{Si}$ $[\text{M}+\text{H}]^+$: 339.2430; found: 339.2436.




(E)-1,3-di-tert-butyl-5-(2-methyl-5-(p-tolyl)pent-4-en-2-yl)benzene (5): Column chromatography (SiO_2 5 g, eluent: Hexane 100%) afforded **5** (24.7 mg, 68%) as colorless oil. R_f = 0.8 (Hexane 100%). ^1H NMR (400 MHz, CDCl_3) δ = 7.27 (s, 1H), 7.24 (d, J = 1.6 Hz, 2H), 7.17 (d, J = 8.1 Hz, 2H), 7.07 (d, J = 8.0 Hz, 2H), 6.32 (d, J = 15.8 Hz, 1H), 5.99 (dt, J = 15.4, 7.4 Hz, 1H), 2.48 (d, J = 7.4 Hz, 2H), 2.31 (s, 3H), 1.36 (s, 6H), 1.34 (s, 18H) ppm. ^{13}C NMR (101 MHz, CDCl_3) δ = 149.9, 136.5, 131.8, 139.3, 139.1, 126.9, 125.8, 120.0, 119.4, 48.2, 38.5, 35.0, 31.6, 30.3, 28.6, 21.1 ppm. HRMS m/z (HESI-II) calcd. for $\text{C}_{27}\text{H}_{38}$ $[\text{M}+\text{Na}]^+$: 385.2865; found: 385.2866.




(3-(3,5-di-tert-butylphenyl)-3-methylbutyl)trimethylsilane (7): Column chromatography (SiO_2 5 g, eluent: Hexane 100%) afforded **7** (26.6 mg, 80%) as colorless oil. R_f = 0.8 (Hexane 100%). ^1H NMR (400 MHz, CDCl_3) δ = 7.24 (s, 1H), 7.17 (d, J = 1.7 Hz, 2H), 1.62-1.57 (m, 2H), 1.34 (s, 18H), 1.29 (s, 6H), 0.30-0.22 (m, 2H), -0.06 (s, 9H) ppm. ^{13}C NMR (101 MHz, CDCl_3) δ = 149.7, 148.3, 120.2, 119.1, 38.9, 38.4, 34.9, 31.6, 28.7, 10.9, -1.9 ppm. HRMS m/z (APCI) calcd. for $\text{C}_{22}\text{H}_{40}\text{Si}$ $[\text{M}+\text{H}]^+$: 333.2972; found: 333.2972.



1,3-di-tert-butyl-5-(2-methyl-5-phenylpent-4-yn-2-yl)benzene (9a): Column chromatography (SiO₂ 5 g, eluent: Hexane 100%) afforded **9a** (32.6 mg, 94%) as yellow oil; $R_f = 0.8$ (Hexane 100%). ¹H NMR (500 MHz, CDCl₃) $\delta = 7.34$ (d, $J = 4.9$ Hz, 2H), 7.30 (s, 2H), 7.23 (s, 3H), 2.68 (s, 2H), 1.48 (s, 6H), 1.31 (s, 18H) ppm. ¹³C NMR (126 MHz, CDCl₃) $\delta = 150.0, 147.5, 131.5, 128.1, 127.5, 124.0, 119.9, 119.9, 88.6, 82.5, 38.4, 35.0, 34.9, 31.6, 28.5$ ppm. HRMS m/z (APCI) calcd. for C₂₆H₃₄ [M+H]⁺: 347.2733; found: 347.2732.




1,3-di-tert-butyl-5-(2-methyl-5-(p-tolyl)pent-4-yn-2-yl)benzene (9b): Column chromatography (SiO₂ 5 g, eluent: Hexane 100%) afforded **9b** (33.5 mg, 93%) as colourless oil; $R_f = 0.8$ (Hexane 100%). ¹H NMR (500 MHz, CDCl₃) $\delta = 7.31$ (s, 2H), 7.25 (d, $J = 7.4$ Hz, 3H), 7.07 (d, $J = 7.6$ Hz, 2H), 2.69 (s, 2H), 2.32 (s, 3H), 1.49 (s, 6H), 1.33 (s, 18H) ppm. ¹³C NMR (126 MHz, CDCl₃) $\delta = 150.0, 147.6, 137.4, 131.4, 128.9, 121.0, 119.9, 119.9, 87.8, 82.5, 38.4, 35.0, 34.9, 31.6, 28.5, 21.4$ ppm. HRMS m/z (APCI) calcd. for C₂₇H₃₆ [M+H]⁺: 361.2890; found: 361.2884.




1,3-di-tert-butyl-5-(5-(2-methoxyphenyl)-2-methylpent-4-yn-2-yl)benzene (9c): Column chromatography (SiO₂ 5 g, eluent: Hexane 100%) afforded **9c** (35.1 mg, 93%) as colourless oil; $R_f = 0.6$ (Hexane/EA = 100/1). ¹H NMR (500 MHz, CDCl₃) $\delta = 7.31$ (d, $J = 10.3$ Hz, 3H), 7.28


(s, 1H), 7.26 – 7.19 (m, 1H), 6.85 (t, $J = 8.4$ Hz, 2H), 3.85 (s, 3H), 2.76 (s, 2H), 1.52 (s, 6H), 1.33 (s, 18H) ppm. ^{13}C NMR (126 MHz, CDCl_3) $\delta = 159.9, 150.0, 147.7, 133.5, 128.8, 120.3, 119.9, 119.9, 113.2, 110.5, 92.9, 78.6, 55.7, 38.5, 35.2, 35.0, 31.5, 28.4$ ppm. HRMS m/z (APCI) calcd. for $\text{C}_{27}\text{H}_{36}\text{O}$ $[\text{M}+\text{H}]^+$: 377.2839; found: 377.2835.




1,3-di-tert-butyl-5-(5-(3-methoxyphenyl)-2-methylpent-4-yn-2-yl)benzene (9d): Column chromatography (SiO_2 5 g, eluent: Hexane 100%) afforded **9d** (35.8 mg, 95%) as colourless oil; $R_f = 0.6$ (Hexane/EA = 100/1). ^1H NMR (500 MHz, CDCl_3) $\delta = 7.29$ (d, $J = 13.2$ Hz, 3H), 7.16 (t, $J = 7.9$ Hz, 1H), 6.95 (d, $J = 7.5$ Hz, 1H), 6.88 (s, 1H), 6.81 (d, $J = 8.3$ Hz, 1H), 3.77 (s, 3H), 2.69 (s, 2H), 1.49 (s, 6H), 1.33 (s, 18H) ppm. ^{13}C NMR (126 MHz, CDCl_3) $\delta = 159.2, 150.0, 147.5, 129.2, 125.0, 124.1, 119.9, 119.9, 116.3, 114.1, 88.5, 82.4, 55.2, 38.4, 35.0, 34.9, 31.6, 28.5$ ppm. HRMS m/z (APCI) calcd. for $\text{C}_{27}\text{H}_{36}\text{O}$ $[\text{M}+\text{H}]^+$: 377.2839; found: 377.2834.




1,3-di-tert-butyl-5-(5-(4-methoxyphenyl)-2-methylpent-4-yn-2-yl)benzene (9e): Column chromatography (SiO_2 5 g, eluent: Hexane 100%) afforded **9d** (30.2 mg, 80%) as colourless liquid; $R_f = 0.6$ (Hexane/EA = 100/1) ^1H NMR (500 MHz, CDCl_3) $\delta = 7.31 - 7.28$ (m, 5H), 6.79 (d, $J = 8.3$ Hz, 2H), 3.78 (s, 3H), 2.68 (s, 2H), 1.49 (s, 6H), 1.33 (s, 18H) ppm. ^{13}C NMR (126 MHz, CDCl_3) $\delta = 158.9, 150.0, 147.6, 132.8, 119.9, 116.2, 113.7, 86.9, 82.2, 55.2, 38.4, 35.0, 34.9, 31.6, 28.5$ ppm. HRMS m/z (APCI) calcd. for $\text{C}_{27}\text{H}_{36}\text{O}$ $[\text{M}+\text{H}]^+$: 377.2839; found: 377.2835.



1,3-di-tert-butyl-5-(5-(2-fluorophenyl)-2-methylpent-4-yn-2-yl)benzene (9f): Column chromatography (SiO₂ 5 g, eluent: hexane 100%) afforded **9f** (31.0 mg, 85%) as colourless liquid; ¹H NMR (500 MHz, CDCl₃) δ = 7.38 – 7.35 (m, 3H), 7.32 (s, 1H), 7.26 (dd, *J* = 13.8, 7.8 Hz, 1H), 7.07 (t, *J* = 8.2 Hz, 2H), 2.77 (s, 2H), 1.55 (s, 6H), 1.36 (s, 18H) ppm. ¹³C NMR (126 MHz, CDCl₃) δ = 163.9, 161.9, 150.1, 147.5, 133.5, 129.1, 129.1, 123.7, 123.7, 120.0, 120.0, 115.4, 115.3, 112.6, 112.5, 94.2, 94.2, 75.8, 38.4, 35.1, 35.0, 31.6, 31.6, 28.4, 22.7, 14.2 ppm. ¹⁹F NMR (471 MHz, CDCl₃) δ = -110.76 ppm. HRMS *m/z* (APCI) calcd. for C₂₆H₃₃F [M+H]⁺: 365.2639; found: 365.2642.




1,3-di-tert-butyl-5-(5-(3-fluorophenyl)-2-methylpent-4-yn-2-yl)benzene (9g): Column chromatography (SiO₂ 5 g, eluent: Hexane 100%) afforded **9g** (32.9 mg, 90%) as colourless liquid; *R_f* = 0.8 (Hexane 100%). ¹H NMR (500 MHz, CDCl₃) δ = 7.30 (s, 3H), 7.21 (dd, *J* = 14.5, 7.3 Hz, 1H), 7.11 (d, *J* = 7.6 Hz, 1H), 7.02 (d, *J* = 9.5 Hz, 1H), 6.96 (t, *J* = 8.4 Hz, 1H), 2.69 (s, 2H), 1.49 (s, 6H), 1.33 (s, 18H) ppm. ¹³C NMR (126 MHz, CDCl₃) δ = 163.3, 161.3, 150.1, 147.3, 129.7, 129.6, 127.4, 127.4, 125.9, 125.9, 120.0, 119.8, 118.4, 118.2, 114.9, 114.7, 89.9, 81.5, 81.4, 38.4, 35.0, 34.9, 31.6, 28.6 ppm. ¹⁹F NMR (471 MHz, CDCl₃) δ = -113.52 ppm. HRMS *m/z* (APCI) calcd. for C₂₆H₃₃F [M+H]⁺: 365.2639; found: 365.2638.




1,3-di-tert-butyl-5-(5-(4-fluorophenyl)-2-methylpent-4-yn-2-yl)benzene (9h): Column chromatography (SiO₂ 5 g, eluent: Hexane 100%) afforded **9h** (33.9 mg, 93%) as yellow solid; m.p. 54–56 °C; *R_f* = 0.8 (Hexane 100%). ¹H NMR (500 MHz, CDCl₃) δ = 7.31 (dd, *J* = 11.5,


5.7 Hz, 5H), 6.95 (t, $J = 8.2$ Hz, 1H), 2.68 (s, 2H), 1.49 (s, 6H), 1.33 (s, 18H) ppm. ^{13}C NMR (126 MHz, CDCl_3) $\delta = 163.0, 161.0, 150.0, 147.4, 133.3, 133.2, 127.9, 127.9, 119.9, 119.8, 115.4, 115.2, 88.3, 81.4, 38.4, 35.0, 34.8, 31.6, 28.5$ ppm. ^{19}F NMR (471 MHz, CDCl_3) $\delta = -112.34$ ppm. HRMS m/z (APCI) calcd. for $\text{C}_{26}\text{H}_{33}\text{F}$ $[\text{M}+\text{H}]^+$: 365.2639; found: 365.2642.




1,3-di-tert-butyl-5-(2-methyl-5-(4-(trifluoromethyl)phenyl)pent-4-yn-2-yl)benzene (9i): Column chromatography (SiO_2 5 g, eluent: Hexane 100%) afforded **9i** (39.0 mg, 94%) as yellow solid: m.p. 61–63 °C; $R_f = 0.8$ (Hexane 100%). ^1H NMR (500 MHz, CDCl_3) $\delta = 7.51$ (d, $J = 8.5$ Hz, 2H), 7.43 (d, $J = 8.0$ Hz, 2H), 7.30 (s, 3H), 2.72 (s, 2H), 1.50 (s, 6H), 1.33 (s, 18H) ppm. ^{13}C NMR (126 MHz, CDCl_3) $\delta = 150.1, 147.2, 131.7, 129.3, 129.1, 127.9, 125.1, 125.0, 120.0, 119.8, 91.6, 81.4, 38.4, 35.0, 34.9, 31.6, 28.6$ ppm. ^{19}F NMR (471 MHz, CDCl_3) $\delta = -62.70$ ppm. HRMS m/z (APCI) calcd. for $\text{C}_{27}\text{H}_{33}\text{F}_3$ $[\text{M}+\text{H}]^+$: 415.2607; found: 415.2606.




4-(4-(3,5-di-tert-butylphenyl)-4-methylpent-1-yn-1-yl)benzonitrile (9j): Column chromatography (SiO_2 5 g, eluent: Hexane/ $\text{Et}_2\text{O} = 50/1$) afforded **9j** (28.0 mg, 75%) as white solid: m.p. 89–91 °C; $R_f = 0.7$ (Hexane 100%). ^1H NMR (500 MHz, CDCl_3) $\delta = 7.55 - 7.53$ (m, 2H), 7.40 – 7.38 (m, 2H), 7.29 (s, 3H), 2.73 (s, 2H), 1.49 (s, 6H), 1.33 (s, 18H) ppm. ^{13}C NMR (126 MHz, CDCl_3) $\delta = 150.2, 147.1, 132.1, 131.9, 129.1, 120.1, 119.8, 118.7, 110.8, 94.1, 81.4, 38.5, 35.0, 31.6, 28.7$ ppm. HRMS m/z (APCI) calcd. for $\text{C}_{27}\text{H}_{33}\text{N}$ $[\text{M}+\text{H}]^+$: 372.2686; found: 372.2689.



methyl 4-(4-(3,5-di-*tert*-butylphenyl)-4-methylpent-1-yn-1-yl)benzoate (9k): Column chromatography (SiO₂ 5 g, eluent: Hexane/Et₂O = 100/1) afforded **9k** (38.0 mg, 94%) as white solid: m.p. 68–70 °C; *R*_f = 0.6 (Hexane/EA = 10/1). ¹H NMR (500 MHz, CDCl₃) δ = 7.93 (d, *J* = 7.7 Hz, 2H), 7.39 (d, *J* = 7.7 Hz, 2H), 7.30 (d, *J* = 5.6 Hz, 3H), 3.90 (s, 3H), 2.72 (s, 2H), 1.50 (s, 6H), 1.33 (s, 18H) ppm. ¹³C NMR (126 MHz, CDCl₃) δ = 166.7, 150.1, 147.2, 131.4, 129.3, 128.9, 128.8, 120.0, 119.8, 92.3, 82.0, 52.1, 38.4, 35.0, 31.6, 28.6 ppm. HRMS *m/z* (APCI) calcd. for C₂₈H₃₆O₂ [M+H]⁺: 405.2788; found: 405.2783.




1-(4-(4-(3,5-di-*tert*-butylphenyl)-4-methylpent-1-yn-1-yl)phenyl)ethan-1-one (9l): Column chromatography (SiO₂ 5 g, eluent: Hexane/Et₂O = 50/1) afforded **9l** (32.0 mg, 82%) as white solid: m.p. 88–90 °C; *R*_f = 0.7 (Hexane/EA = 50/1). ¹H NMR (500 MHz, CDCl₃) δ = 7.86 (d, *J* = 7.7 Hz, 2H), 7.41 (d, *J* = 7.7 Hz, 2H), 7.30 (d, *J* = 5.0 Hz, 3H), 2.73 (s, 2H), 2.58 (s, 3H), 1.50 (s, 6H), 1.33 (s, 18H) ppm. ¹³C NMR (126 MHz, CDCl₃) δ = 197.4, 150.1, 147.2, 135.6, 131.6, 129.1, 128.1, 120.0, 119.8, 92.7, 82.0, 38.4, 35.0, 35.0, 31.6, 28.6, 26.6 ppm. HRMS *m/z* (APCI) calcd. for C₂₈H₃₆O [M+H]⁺: 389.2839; found: 389.2835.




1,3-di-*tert*-butyl-5-(2-methyl-5-(4-nitrophenyl)pent-4-yn-2-yl)benzene (9m): Column chromatography (SiO₂ 5 g, eluent: Hexane/Et₂O = 100/1) afforded **9m** (29.0 mg, 74%) as yellow solid: m.p. 123–125 °C; *R*_f = 0.5 (Hexane/EA = 100/1). ¹H NMR (500 MHz, CDCl₃) δ

= 8.13 (d, $J = 8.0$ Hz, 2H), 7.44 (d, $J = 8.5$ Hz, 2H), 7.30 (s, 3H), 2.75 (s, 2H), 2.58 (s, 3H), 1.50 (s, 6H), 1.33 (s, 18H) ppm. ^{13}C NMR (126 MHz, CDCl_3) $\delta = 150.2, 147.0, 146.5, 132.2, 131.1, 123.4, 120.1, 119.8, 95.1, 81.2, 38.5, 35.0, 35.0, 31.6, 28.7$ ppm. HRMS m/z (APCI) calcd. for $\text{C}_{26}\text{H}_{33}\text{NO}_2$ $[\text{M}+\text{H}]^+$: 392.2584; found: 392.2587.




1,3-di-tert-butyl-5-(5-(3,5-dimethoxyphenyl)-2-methylpent-4-yn-2-yl)benzene (9n):

Column chromatography (SiO_2 5 g, eluent: Hexane/ $\text{Et}_2\text{O} = 10/1$) afforded **9n** (38.0 mg, 93%) as colourless liquid; $R_f = 0.6$ (Hexane/EA = 50/1). ^1H NMR (500 MHz, CDCl_3) $\delta = 7.35$ (d, $J = 13.8$ Hz, 3H), 6.57 (s, 2H), 6.44 (s, 1H), 3.80 (s, 6H), 2.74 (s, 2H), 1.54 (s, 6H), 1.39 (s, 18H) ppm. ^{13}C NMR (126 MHz, CDCl_3) $\delta = 160.4, 150.0, 147.4, 125.3, 119.9, 119.9, 109.3, 101.1, 88.3, 82.5, 55.3, 38.4, 35.0, 34.8, 31.6, 28.6$ ppm. HRMS m/z (APCI) calcd. for $\text{C}_{28}\text{H}_{38}\text{O}_2$ $[\text{M}+\text{H}]^+$: 407.2945; found: 407.2942.




4-(4-(3,5-di-tert-butylphenyl)-4-methylpent-1-yn-1-yl)-N,N-dimethylaniline (9o): Column chromatography (SiO_2 5 g, eluent: Hexane/ $\text{Et}_2\text{O} = 100/1$) afforded **9o** (30.0 mg, 77%) as colourless liquid; $R_f = 0.6$ (Hexane/EA = 50/1). ^1H NMR (500 MHz, CDCl_3) $\delta = 7.32$ (s, 2H), 7.28 (s, 1H), 7.24 (d, $J = 7.2$ Hz, 2H), 2.94 (s, 6H), 2.68 (s, 2H), 1.48 (s, 6H), 1.33 (s, 18H) ppm. ^{13}C NMR (126 MHz, CDCl_3) $\delta = 149.9, 149.6, 147.8, 132.5, 119.9, 119.8, 111.9, 111.3, 85.8, 83.0, 40.3, 38.4, 35.0, 31.6, 28.5$ ppm. HRMS m/z (APCI) calcd. for $\text{C}_{28}\text{H}_{39}\text{N}$ $[\text{M}+\text{H}]^+$: 390.3155; found: 390.3147.




2-(4-(3,5-di-tert-butylphenyl)-4-methylpent-1-yn-1-yl)-6-methoxynaphthalene (9p):

Column chromatography (SiO₂ 5 g, eluent: Hexane/Et₂O = 100/1) afforded **9p** (36.0 mg, 84%) as white solid: m.p. 109–111 °C; *R_f* = 0.6 (Hexane/EA = 100/1). ¹H NMR (500 MHz, CDCl₃) δ = 7.79 (s, 1H), 7.63 (t, *J* = 10.1 Hz, 2H), 7.37 (d, *J* = 7.3 Hz, 1H), 7.34 (s, 2H), 7.30 (s, 1H), 7.12 (d, *J* = 8.9 Hz, 1H), 7.08 (s, 1H), 3.90 (s, 3H), 2.74 (s, 2H), 1.53 (s, 6H), 1.34 (s, 18H) ppm. ¹³C NMR (126 MHz, CDCl₃) δ = 157.9, 150.0, 147.5, 133.7, 130.8, 129.3, 129.1, 128.5, 126.5, 119.9, 119.2, 119.0, 105.7, 88.2, 82.9, 55.3, 38.5, 35.0, 31.6, 28.6 ppm. HRMS *m/z* (APCI) calcd. for C₃₁H₃₈O [M+H]⁺: 427.2995; found: 427.2992.




3-(4-(3,5-di-tert-butylphenyl)-4-methylpent-1-yn-1-yl)thiophene (9q): Column chromatography (SiO₂ 5 g, eluent: Hexane 100%) afforded **9q** (27.0 mg, 77%) as colourless liquid; *R_f* = 0.7 (Hexane 100%). ¹H NMR (500 MHz, CDCl₃) δ = 7.33 (d, *J* = 1.2 Hz, 3H), 7.30 (d, *J* = 7.7 Hz, 1H), 7.24 (dd, *J* = 4.9, 3.0 Hz, 1H), 7.06 (d, *J* = 4.9 Hz, 1H), 2.68 (s, 2H), 1.48 (s, 6H), 1.33 (s, 18H) ppm. ¹³C NMR (126 MHz, CDCl₃) δ = 150.0, 147.4, 130.0, 127.5, 124.9, 123.0, 119.9, 119.9, 119.0, 88.1, 77.5, 38.3, 35.0, 34.9, 31.6, 28.5 ppm. HRMS *m/z* (APCI) calcd. for C₂₄H₃₂S [M+H]⁺: 353.2298; found: 353.2301.




2-(4-(3,5-di-tert-butylphenyl)-4-methylpent-1-yn-1-yl)pyridine (9r): Column chromatography (SiO₂ 5 g, eluent: Hexane/Et₂O = 15/1) afforded **9r** (28.9 mg, 83%) as colourless liquid; *R_f* = 0.8 (Hexane/EA = 100/1). ¹H NMR (500 MHz, CDCl₃) δ = 8.54 (d, *J* =


5.0 Hz, 1H), 7.59 (t, $J = 8.0$ Hz, 1H), 7.31 – 7.29 (m, 4H), 7.17 (t, $J = 6.0$ Hz, 1H), 2.74 (s, 2H), 1.52 (s, 6H), 1.33 (s, 18H) ppm. ^{13}C NMR (126 MHz, CDCl_3) $\delta = 150.1, 149.8, 147.3, 143.9, 135.9, 126.9, 122.2, 120.0, 119.8, 89.3, 82.3, 38.3, 35.0, 34.8, 31.5, 28.5$ ppm. HRMS m/z (APCI) calcd. for $\text{C}_{25}\text{H}_{33}\text{N}$ $[\text{M}+\text{H}]^+$: 348.2686; found: 348.2684.




3-(4-(3,5-di-*tert*-butylphenyl)-4-methylpent-1-yn-1-yl)pyridine (9s): Column chromatography (SiO_2 5 g, eluent: Hexane 100%) afforded **9s** (31.0 mg, 89%) as white solid: m.p. 56–58 °C; $R_f = 0.8$ (Hexane/EA = 100/1). ^1H NMR (500 MHz, CDCl_3) $\delta = 8.57$ (s, 1H), 8.47 (d, $J = 4.5$ Hz, 1H), 7.61 (d, $J = 7.5$ Hz, 1H), 7.30 (s, 3H), 7.18 (dd, $J = 8.0, 5.0$ Hz, 1H), 2.72 (s, 2H), 1.50 (s, 6H), 1.33 (s, 18H) ppm. ^{13}C NMR (126 MHz, CDCl_3) $\delta = 152.3, 150.1, 147.9, 147.1, 138.3, 122.8, 121.1, 120.0, 119.8, 92.4, 79.3, 38.4, 35.0, 34.9, 31.6, 28.6$ ppm. HRMS m/z (APCI) calcd. for $\text{C}_{25}\text{H}_{33}\text{N}$ $[\text{M}+\text{H}]^+$: 348.2686; found: 348.2685.




1,3-di-*tert*-butyl-5-(5-cyclopropyl-2-methylpent-4-yn-2-yl)benzene (9t): Column chromatography (SiO_2 5 g, eluent: Hexane 100%) afforded **9t** (27.0 mg, 87%) as colourless liquid; $R_f = 0.8$ (Hexane 100%). ^1H NMR (500 MHz, CDCl_3) $\delta = 7.25$ (d, $J = 5.0$ Hz, 3H), 2.40 (s, 2H), 1.39 (s, 6H), 1.33 (s, 18H), 1.19 (d, $J = 7.0$ Hz, 1H), 0.67 (t, $J = 9.3$ Hz, 2H), 0.56 (d, $J = 4.6$ Hz, 2H) ppm. ^{13}C NMR (126 MHz, CDCl_3) $\delta = 149.9, 147.7, 119.9, 119.8, 85.3, 73.7, 38.2, 35.0, 34.3, 31.6, 28.4, 8.0, -0.4$ ppm. HRMS m/z (APCI) calcd. for $\text{C}_{23}\text{H}_{34}$ $[\text{M}+\text{H}]^+$: 311.2733; found: 311.2732.



1,3-di-tert-butyl-5-(5-cyclopentyl-2-methylpent-4-yn-2-yl)benzene (9u): Column chromatography (SiO₂ 5 g, eluent: Hexane 100%) afforded **9u** (24.7 mg, 73%) as colourless liquid; $R_f = 0.8$ (Hexane 100%). ¹H NMR (500 MHz, CDCl₃) $\delta = 7.26$ (s, 3H), 2.56 (d, $J = 6.3$ Hz, 1H), 2.44 (s, 2H), 1.83 (s, 2H), 1.66 (s, 2H), 1.51 (t, $J = 20.3$ Hz, 4H), 1.40 (s, 6H), 1.33 (s, 18H) ppm. ¹³C NMR (126 MHz, CDCl₃) $\delta = 149.9, 147.9, 119.9, 119.8, 86.6, 77.9, 38.2, 35.0, 34.3, 34.1, 31.6, 30.4, 28.4, 24.8$ ppm. HRMS m/z (APCI) calcd. for C₂₅H₃₈ [M+H]⁺: 339.3046; found: 339.3047.




1,3-di-tert-butyl-5-(5-cyclohexyl-2-methylpent-4-yn-2-yl)benzene (9v): Column chromatography (SiO₂ 5 g, eluent: Hexane 100%) afforded **9v** (29.0 mg, 82%) as colourless liquid; $R_f = 0.8$ (Hexane 100%). ¹H NMR (500 MHz, CDCl₃) $\delta = 7.25$ (s, 3H), 2.46 (s, 2H), 2.34 (d, $J = 31.7$ Hz, 1H), 1.71 (d, $J = 8.5$ Hz, 2H), 1.63 (d, $J = 6.6$ Hz, 2H), 1.45 (t, $J = 11.3$ Hz, 1H), 1.43 – 1.36 (m, 8H), 1.33 (s, 18H), 1.27 (d, $J = 8.7$ Hz, 3H) ppm. ¹³C NMR (126 MHz, CDCl₃) $\delta = 149.9, 147.9, 119.9, 119.8, 86.5, 78.3, 38.2, 35.0, 34.3, 33.1, 31.6, 29.1, 28.4, 26.0, 24.7$ ppm. HRMS m/z (APCI) calcd. for C₂₆H₄₀ [M+H]⁺: 353.3203; found: 353.3207.




1,3-di-tert-butyl-5-(5-(cyclohex-1-en-1-yl)-2-methylpent-4-yn-2-yl)benzene (9w): Column chromatography (SiO₂ 5 g, eluent: Hexane 100%) afforded **9w** (29.8 mg, 85%) as colourless liquid; $R_f = 0.8$ (Hexane 100%). ¹H NMR (500 MHz, CDCl₃) $\delta = 7.26$ (s, 3H), 5.98 (t, $J = 3.5$


Hz, 1H), 2.58 (s, 2H), 2.07 – 2.05 (m, 4H), 1.61 – 1.54 (m, 4H), 1.43 (s, 6H), 1.33 (s, 18H) ppm. ^{13}C NMR (126 MHz, CDCl_3) δ = 149.9, 147.7, 133.1, 121.0, 119.9, 119.8, 85.5, 84.3, 38.3, 35.0, 34.8, 31.6, 29.6, 28.4, 25.5, 22.4, 21.6 ppm. HRMS m/z (APCI) calcd. for $\text{C}_{26}\text{H}_{38}$ $[\text{M}+\text{H}]^+$: 351.3046; found: 351.3045.



(4-(3,5-di-tert-butylphenyl)-4-methylpent-1-yn-1-yl)trimethylsilane (9x): Column chromatography (SiO_2 5 g, eluent: Hexane 100%) afforded **9x** (33.0 mg, 96%) as colourless liquid; R_f = 0.8 (Hexane 100%). ^1H NMR (500 MHz, CDCl_3) δ = 7.26 (s, 3H), 2.52 (s, 2H), 1.43 (s, 6H), 1.33 (s, 18H), 1.12 (s, 9H) ppm. ^{13}C NMR (126 MHz, CDCl_3) δ = 150.0, 147.5, 119.9, 119.8, 105.7, 86.4, 38.0, 35.2, 35.0, 31.6, 28.3, 0.1 ppm. HRMS m/z (APCI) calcd. for $\text{C}_{23}\text{H}_{38}\text{Si}$ $[\text{M}+\text{H}]^+$: 343.2816; found: 343.2815.




1,3-di-tert-butyl-5-(2,6,6-trimethylhept-4-yn-2-yl)benzene (9y): Column chromatography (SiO_2 5 g, eluent: Hexane 100%) afforded **9y** (24.4 mg, 70%) as colourless liquid; R_f = 0.8 (Hexane 100%). ^1H NMR (500 MHz, CDCl_3) δ = 7.30 – 7.28 (m, 3H), 2.47 (s, 2H), 1.44 (s, 6H), 1.36 (s, 18H), 1.20 (s, 9H) ppm. ^{13}C NMR (126 MHz, CDCl_3) δ = 149.9, 148.0, 119.8, 119.7, 90.8, 76.7, 38.2, 35.0, 34.1, 31.6, 31.3, 28.3, 27.4 ppm. HRMS m/z (ESI) calcd. for $\text{C}_{24}\text{H}_{38}$ $[\text{M}+\text{Na}]^+$: 349.2866; found: 349.2863.




1,3-di-tert-butyl-5-(5-ferrocenyl-2-methylpent-4-yn-2-yl)benzene (9z): Column chromatography (SiO_2 5 g, eluent: Hexane 100%) afforded **9z** (36.4 mg, 88%) as dark red oil;

$R_f = 0.8$ (Hexane 100%). $^1\text{H NMR}$ (500 MHz, CDCl_3) $\delta = 7.31$ (d, $J = 6.1$ Hz, 3H), 4.31 (dd, $J = 21.1, 5.0$ Hz, 2H), 4.12 (s, 7H), 2.63 (s, 2H), 1.50 (s, 6H), 1.37 (s, 18H) ppm. $^{13}\text{C NMR}$ (126 MHz, CDCl_3) $\delta = 150.0, 147.6, 119.9, 119.9, 84.5, 80.0, 71.1, 69.6, 68.1, 66.4, 38.3, 35.0, 34.9, 31.6, 28.7$ ppm. HRMS m/z (ESI) calcd. for $\text{C}_{30}\text{H}_{38}\text{Fe}$ $[\text{M}]^+$: 454.2318; found: 454.2316.




1-(tert-butyl)-3-methyl-5-(2-methyl-5-phenylpent-4-yn-2-yl)benzene (9aa): Column chromatography (SiO_2 5 g, eluent: Hexane 100%) afforded **9aa** (13.7 mg, 45%) as colourless liquid; $R_f = 0.8$ (Hexane 100%). $^1\text{H NMR}$ (500 MHz, CDCl_3) $\delta = 7.37 - 7.32$ (m, 2H), 7.29 (d, $J = 7.8$ Hz, 1H), 7.27 - 7.23 (m, 3H), 7.06 (t, $J = 8.8$ Hz, 2H), 2.68 (s, 2H), 2.36 (s, 3H), 1.48 (s, 6H), 1.31 (s, 9H) ppm. $^{13}\text{C NMR}$ (126 MHz, CDCl_3) $\delta = 150.6, 148.1, 136.9, 131.5, 128.1, 127.5, 124.0, 123.8, 123.7, 119.8, 88.5, 82.5, 38.1, 34.8, 34.7, 31.5, 28.4, 21.9$ ppm. HRMS m/z (APCI) calcd. for $\text{C}_{23}\text{H}_{28}$ $[\text{M}+\text{H}]^+$: 305.2264; found: 305.2259.




(R)-6-((5-(3,5-di-tert-butylphenyl)-5-methylhex-2-yn-1-yl)oxy)-2,8-dimethyl-2-((4R,8R)-4,8,12-trimethyltridecyl)chromane (9ab): Column chromatography (SiO_2 5 g, eluent: Hexane 100%) afforded **9ab** (50.7 mg, 74%) as yellow liquid; $R_f = 0.4$ (Hexane 100%). $^1\text{H NMR}$ (500 MHz, CDCl_3) $\delta = 7.30$ (d, $J = 1.5$ Hz, 1H), 7.29 - 7.27 (m, 2H), 6.65 (d, $J = 2.7$ Hz, 1H), 6.55 (d, $J = 2.8$ Hz, 1H), 4.61 (s, 2H), 2.81 - 2.64 (m, 2H), 2.54 (s, 2H), 2.16 (s, 3H), 1.87 - 1.70 (m, 2H), 1.60 (s, 3H), 1.58 - 1.52 (m, 2H), 1.43 (s, 6H), 1.35 (s, 18H), 1.33 - 1.02 (m, 19H), 0.91 - 0.85 (m, 12H) ppm. $^{13}\text{C NMR}$ (126 MHz, CDCl_3) $\delta = 150.3, 150.0, 147.4, 146.6, 127.1, 120.8, 119.9, 119.8, 116.0, 112.6, 85.9, 77.6, 75.6, 57.1, 40.0, 39.4, 38.1, 37.5, 37.4, 37.4, 37.3, 35.0, 34.3, 32.8, 32.7, 31.6, 31.3, 28.3, 28.0, 24.8, 24.4, 24.1, 22.7, 22.6, 21.0, 19.7, 19.6, 16.2$ ppm. HRMS m/z (APCI) calcd. for $\text{C}_{48}\text{H}_{76}\text{O}_2$ $[\text{M}+\text{H}]^+$: 685.5918; found: 685.5914.

5. X-ray Crystallographic Data



≡



Identification code	CCDC 2109330
Empirical formula	C ₂₆ H ₃₃ NO ₂
Formula weight	391.53
Temperature/K	173.15
Crystal system	triclinic
Space group	P-1
a/Å	9.642(14)
b/Å	9.850(15)
c/Å	13.156(18)
α/°	85.36(3)
β/°	76.56(4)
γ/°	74.27(3)
Volume/Å ³	1170(3)
Z	2
ρ _{calc} /g/cm ³	1.112
μ/mm ⁻¹	0.069
F(000)	424.0
Crystal size/mm ³	0.5 × 0.4 × 0.3
Radiation	MoKα (λ = 0.71073)
2θ range for data collection/°	5.352 to 50.49
Index ranges	-11 ≤ h ≤ 11, -11 ≤ k ≤ 11, -15 ≤ l ≤ 15
Reflections collected	29741
Independent reflections	4226 [R _{int} = 0.0478, R _{sigma} = 0.0351]
Data/restraints/parameters	4226/0/319
Goodness-of-fit on F ₂	1.065
Final R indexes [I >= 2σ (I)]	R ₁ = 0.1196, wR ₂ = 0.3217
Final R indexes [all data]	R ₁ = 0.1483, wR ₂ = 0.3520
Largest diff. peak/hole / e Å ⁻³	0.84/-0.53


6. References

1. J. Pan, M. Su, S. L. Buchwald, Palladium(0)-Catalyzed Intermolecular Amination of Unactivated C(sp³)-H Bonds, *Angew. Chem., Int. Ed.* 2011, **50**, 8647–8651.
2. T. E. Barder, S. D. Walker, J. R. Martinelli, S. L. Buchwald, Catalysts for Suzuki–Miyaura Coupling Processes: Scope and Studies of the Effect of Ligand Structure, *J. Am. Chem. Soc.* 2005, **127**, 4685–4696.
3. T. Hoshi, T. Honma, A. Mori, M. Konishi, T. Sato, H. Hagihira, T. Suzuki, An Active, General, and Long-Lived Palladium Catalyst for Cross-Couplings of Deactivated (Hetero)aryl Chlorides and Bromides with Arylboronic Acids, *J. Org. Chem.* 2013, **78**, 11513–11524.
4. H. Chen, M. Yang, G. Wang, L. Gao, Z. Ni, J. Zou, S. Li, B(C₆F₅)₃-Catalyzed Sequential Additions of Terminal Alkynes to *para*-Substituted Phenols: Selective Construction of Congested Phenol-Substituted Quaternary Carbons, *Org. Lett.* 2021, **23**, 5533–5538.


7 . Copies of ^1H NMR, ^{13}C NMR, ^{19}F NMR Spectra

2,6-di-*tert*-butyl-4-methylphenyl trifluoromethanesulfonate (1c)

^1H NMR (400 MHz, CDCl_3)




^{13}C NMR (101 MHz, CDCl_3)




1,3-di-*tert*-butyl-5-(2-methyl-1-phenylpropan-2-yl)benzene (3a)

$^1\text{H NMR}$ (500 MHz, CDCl_3)




$^{13}\text{C NMR}$ (126 MHz, CDCl_3)




1,3-di-*tert*-butyl-5-(1-(2-methoxyphenyl)-2-methylpropan-2-yl)benzene (3b)

^1H NMR (500 MHz, CDCl_3)




^{13}C NMR (126 MHz, CDCl_3)




1,3-di-*tert*-butyl-5-(1-(3-methoxyphenyl)-2-methylpropan-2-yl) (3c)

^1H NMR (400 MHz, CDCl_3)




^{13}C NMR (101 MHz, CDCl_3)




1,3-di-*tert*-butyl-5-(1-(4-methoxyphenyl)-2-methylpropan-2-yl)benzene (3d)

^1H NMR (500 MHz, CDCl_3)




^{13}C NMR (126 MHz, CDCl_3)




1,3-di-*tert*-butyl-5-(2-methyl-1-(*m*-tolyl)propan-2-yl)benzene (3e)

^1H NMR (400 MHz, CDCl_3)




^{13}C NMR (101 MHz, CDCl_3)




1,3-di-*tert*-butyl-5-(2-methyl-1-(*o*-tolyl)propan-2-yl)benzene (3f)

^1H NMR (500 MHz, CDCl_3)




^{13}C NMR (126 MHz, CDCl_3)




1,3-di-*tert*-butyl-5-(2-methyl-1-(3-(trifluoromethyl)phenyl)propan-2-yl)benzene (3g)

$^1\text{H NMR}$ (500 MHz, CDCl_3)




$^{13}\text{C NMR}$ (126 MHz, CDCl_3)




1,3-di-*tert*-butyl-5-(2-methyl-1-(2-(trifluoromethyl)phenyl)propan-2-yl)benzene (3h)

^1H NMR (500 MHz, CDCl_3)




^{13}C NMR (126 MHz, CDCl_3)




1-(1-(2-(benzyloxy)phenyl)-2-methylpropan-2-yl)-3,5-di-*tert*-butylbenzene (3i)

$^1\text{H NMR}$ (400 MHz, CDCl_3)




$^{13}\text{C NMR}$ (101 MHz, CDCl_3)




1,3-di-*tert*-butyl-5-(1-(2-(2-methoxyethoxy)phenyl)-2-methylpropan-2-yl)benzene (3j)

^1H NMR (400 MHz, CDCl_3)




^{13}C NMR (101 MHz, CDCl_3)




(4-(2-(3,5-di-*tert*-butylphenyl)-2-methylpropyl)phenyl)trimethylsilane (3k)

^1H NMR (400 MHz, CD_2Cl_2)




^{13}C NMR (101 MHz, CD_2Cl_2)




2-(2-(3,5-di-*tert*-butylphenyl)-2-methylpropyl)-1,3-dimethoxybenzene (3m)

^1H NMR (500 MHz, CDCl_3)




^{13}C NMR (126 MHz, CDCl_3)




2-(2-(3,5-di-*tert*-butylphenyl)-2-methylpropyl)-1,3-dimethylbenzene (3n)

^1H NMR (500 MHz, CDCl_3)




^{13}C NMR (126 MHz, CDCl_3)




5-(2-(3,5-di-*tert*-butylphenyl)-2-methylpropyl)-2-methoxy-1,3-dimethylbenzene (3o)

$^1\text{H NMR}$ (400 MHz, CDCl_3)




$^{13}\text{C NMR}$ (101 MHz, CDCl_3)




1-(2-(3,5-di-*tert*-butylphenyl)-2-methylpropyl)-2,4-dimethoxybenzene (3p)

^1H NMR (400 MHz, CDCl_3)




^{13}C NMR (101 MHz, CDCl_3)




1-(1-(3,5-bis(trifluoromethyl)phenyl)-2-methylpropan-2-yl)-3,5-di-*tert*-butylbenzene (3q)

^1H NMR (400 MHz, CDCl_3)




^{13}C NMR (101 MHz, CDCl_3)




2-(2-(3,5-di-*tert*-butylphenyl)-2-methylpropyl)-1,3,5-triisopropylbenzene (3r)

$^1\text{H NMR}$ (400 MHz, CDCl_3)




$^{13}\text{C NMR}$ (101 MHz, CDCl_3)




(3-(*tert*-butyl)-5-(2-methyl-1-phenylpropan-2-yl)phenyl)trimethylsilane (3s)

^1H NMR (400 MHz, CDCl_3)




^{13}C NMR (101 MHz, CDCl_3)




(E)-1,3-di-tert-butyl-5-(2-methyl-5-(p-tolyl)pent-4-en-2-yl)benzene (5)

$^1\text{H NMR}$ (400 MHz, CDCl_3)




$^{13}\text{C NMR}$ (101 MHz, CDCl_3)




(3-(3,5-di-*tert*-butylphenyl)-3-methylbutyl)trimethylsilane (7)

$^1\text{H NMR}$ (400 MHz, CDCl_3)




$^{13}\text{C NMR}$ (101 MHz, CDCl_3)




(R)-2,8-dimethyl-6-(prop-2-yn-1-yloxy)-2-((4R,8R)-4,8,12-trimethyltridecyl)chromane
(8ab)

$^1\text{H NMR}$ (500 MHz, CDCl_3)




$^{13}\text{C NMR}$ (126 MHz, CDCl_3)




1,3-di-tert-butyl-5-(2-methyl-5-phenylpent-4-yn-2-yl)benzene (9a)

$^1\text{H NMR}$ (500 MHz, CDCl_3)




$^{13}\text{C NMR}$ (126 MHz, CDCl_3)




1,3-di-tert-butyl-5-(2-methyl-5-(p-tolyl)pent-4-yn-2-yl)benzene (9b)

^1H NMR (500 MHz, CDCl_3)




^{13}C NMR (126 MHz, CDCl_3)




1,3-di-tert-butyl-5-(5-(2-methoxyphenyl)-2-methylpent-4-yn-2-yl)benzene (9c)

$^1\text{H NMR}$ (500 MHz, CDCl_3)




$^{13}\text{C NMR}$ (126 MHz, CDCl_3)




1,3-di-tert-butyl-5-(5-(3-methoxyphenyl)-2-methylpent-4-yn-2-yl)benzene (9d)

$^1\text{H NMR}$ (500 MHz, CDCl_3)




$^{13}\text{C NMR}$ (126 MHz, CDCl_3)




1,3-di-tert-butyl-5-(5-(4-methoxyphenyl)-2-methylpent-4-yn-2-yl)benzene (9e)

$^1\text{H NMR}$ (500 MHz, CDCl_3)




$^{13}\text{C NMR}$ (126 MHz, CDCl_3)




1,3-di-tert-butyl-5-(5-(2-fluorophenyl)-2-methylpent-4-yn-2-yl)benzene (9f)



¹H NMR (500 MHz, CDCl₃)



¹³C NMR (126 MHz, CDCl₃)




¹⁹F NMR (471 MHz, CDCl₃)




1,3-di-tert-butyl-5-(5-(3-fluorophenyl)-2-methylpent-4-yn-2-yl)benzene (9g)



¹H NMR (500 MHz, CDCl₃)



¹³C NMR (126 MHz, CDCl₃)




¹⁹F NMR (471 MHz, CDCl₃)




1,3-di-tert-butyl-5-(5-(4-fluorophenyl)-2-methylpent-4-yn-2-yl)benzene (9h)


^1H NMR (500 MHz, CDCl_3)



^{13}C NMR (126 MHz, CDCl_3)



¹⁹F NMR (471 MHz, CDCl₃)




112.3
112.4
112.5

```
Current Data Parameters
NAME      chemp-2-152-1-1
EXPNO    3
PROCNO   1


F2 - Acquisition Parameters
Date_    20201222
Time     12.06 h
INSTRUM  spect
PROBHD   Z119470_0993 (
PULPROG  zgpg30
TD        131072
SOLVENT  CDCl3
NS        16
DS        4
SWH       113636.367 Hz
FIDRES   1.733953 Hz
AQ        0.5767168 sec
RG        206.72
DW        6.400 usec
DE        6.50 usec
TE        295.2 K
D1        1.00000000 sec
TDO       1
SFO1     470.5453180 MHz
NUC1      19F
P1        15.00 usec
PLW1     47.23500061 W

F2 - Processing parameters
SI        65536
SF        470.5923772 MHz
WDW       EM
SSB       0
LB        0.30 Hz
GB        0
PC        1.00
```




1,3-di-tert-butyl-5-(2-methyl-5-(4-(trifluoromethyl)phenyl)pent-4-yn-2-yl)benzene (9i)


¹H NMR (500 MHz, CDCl₃)



¹³C NMR (126 MHz, CDCl₃)




¹⁹F NMR (471 MHz, CDCl₃)




4-(4-(3,5-di-tert-butylphenyl)-4-methylpent-1-yn-1-yl)benzotrile (9j)

^1H NMR (500 MHz, CDCl_3)




^{13}C NMR (126 MHz, CDCl_3)




methyl 4-(4-(3,5-di-tert-butylphenyl)-4-methylpent-1-yn-1-yl)benzoate (9k)

^1H NMR (500 MHz, CDCl_3)




^{13}C NMR (126 MHz, CDCl_3)




1-(4-(4-(3,5-di-tert-butylphenyl)-4-methylpent-1-yn-1-yl)phenyl)ethan-1-one (9l)

$^1\text{H NMR}$ (500 MHz, CDCl_3)




$^{13}\text{C NMR}$ (126 MHz, CDCl_3)




1,3-di-tert-butyl-5-(2-methyl-5-(4-nitrophenyl)pent-4-yn-2-yl)benzene (9m)

$^1\text{H NMR}$ (500 MHz, CDCl_3)




$^{13}\text{C NMR}$ (126 MHz, CDCl_3)




1,3-di-tert-butyl-5-(5-(3,5-dimethoxyphenyl)-2-methylpent-4-yn-2-yl)benzene (9n)

$^1\text{H NMR}$ (500 MHz, CDCl_3)




$^{13}\text{C NMR}$ (126 MHz, CDCl_3)




4-(4-(3,5-di-tert-butylphenyl)-4-methylpent-1-yn-1-yl)-N,N-dimethylaniline (9o)

$^1\text{H NMR}$ (500 MHz, CDCl_3)




$^{13}\text{C NMR}$ (126 MHz, CDCl_3)




2-(4-(3,5-di-tert-butylphenyl)-4-methylpent-1-yn-1-yl)-6-methoxynaphthalene (9p)

¹H NMR (500 MHz, CDCl₃)




¹³C NMR (126 MHz, CDCl₃)




3-(4-(3,5-di-tert-butylphenyl)-4-methylpent-1-yn-1-yl)thiophene (9q)

$^1\text{H NMR}$ (500 MHz, CDCl_3)




$^{13}\text{C NMR}$ (126 MHz, CDCl_3)




3-(4-(3,5-di-tert-butylphenyl)-4-methylpent-1-yn-1-yl)pyridine (9s)

$^1\text{H NMR}$ (500 MHz, CDCl_3)




$^{13}\text{C NMR}$ (126 MHz, CDCl_3)




1,3-di-tert-butyl-5-(5-cyclopropyl-2-methylpent-4-yn-2-yl)benzene (9t)

¹H NMR (500 MHz, CDCl₃)




¹³C NMR (126 MHz, CDCl₃)




1,3-di-tert-butyl-5-(5-cyclopentyl-2-methylpent-4-yn-2-yl)benzene (9u)

¹H NMR (500 MHz, CDCl₃)




¹³C NMR (126 MHz, CDCl₃)




1,3-di-tert-butyl-5-(5-(cyclohex-1-en-1-yl)-2-methylpent-4-yn-2-yl)benzene (9w)

¹H NMR (500 MHz, CDCl₃)




¹³C NMR (126 MHz, CDCl₃)




(4-(3,5-di-tert-butylphenyl)-4-methylpent-1-yn-1-yl)trimethylsilane (9x)

¹H NMR (500 MHz, CDCl₃)




¹³C NMR (126 MHz, CDCl₃)




1,3-di-tert-butyl-5-(2,6,6-trimethylhept-4-yn-2-yl)benzene (9y)

$^1\text{H NMR}$ (500 MHz, CDCl_3)




$^{13}\text{C NMR}$ (126 MHz, CDCl_3)




1,3-di-tert-butyl-5-(5-ferrocenyl-2-methylpent-4-yn-2-yl)benzene (9z)

^1H NMR (500 MHz, CDCl_3)




^{13}C NMR (126 MHz, CDCl_3)



1-(tert-butyl)-3-methyl-5-(2-methyl-5-phenylpent-4-yn-2-yl)benzene (9aa)

^1H NMR (500 MHz, CDCl_3)



^{13}C NMR (126 MHz, CDCl_3)

